Evolutionary conservation of human drug targets in organisms used for environmental risk assessments.
about
Implementing ecopharmacovigilance in practice: challenges and potential opportunitiesCurrent perspectives on the use of alternative species in human health and ecological hazard assessmentsPharmaceuticals and personal care products in the environment: what are the big questions?Pharmacological profiling of zebrafish behavior using chemical and genetic classification of sleep-wake modifiers.From the exposome to mechanistic understanding of chemical-induced adverse effectsSimilar anxiolytic effects of agonists targeting serotonin 5-HT1A or cannabinoid CB receptors on zebrafish behavior in novel environmentsAre pharmaceuticals with evolutionary conserved molecular drug targets more potent to cause toxic effects in non-target organisms?Quantitative cross-species extrapolation between humans and fish: the case of the anti-depressant fluoxetineGABAergic anxiolytic drug in water increases migration behaviour in salmonNeurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish EmbryosMedicating the environment: assessing risks of pharmaceuticals to wildlife and ecosystems.Leveraging existing data for prioritization of the ecological risks of human and veterinary pharmaceuticals to aquatic organisms.Characterization of the Zoarces viviparus liver transcriptome using massively parallel pyrosequencingDiazepam and fluoxetine decrease the stress response in zebrafish.Behavioural and physiological responses of birds to environmentally relevant concentrations of an antidepressant.Assessing variation in the potential susceptibility of fish to pharmaceuticals, considering evolutionary differences in their physiology and ecologyPutting pharmaceuticals into the wider context of challenges to fish populations in rivers.Comparative pharmacology and toxicology of pharmaceuticals in the environment: diphenhydramine protection of diazinon toxicity in Danio rerio but not Daphnia magnaToxicity of anthelmintic drugs (fenbendazole and flubendazole) to aquatic organismsAdverse outcome pathway development II: best practices.Chick embryo chorioallantoic membrane (CAM): an alternative predictive model in acute toxicological studies for anti-cancer drugs.Human pharmaceuticals in the marine environment: Focus on exposure and biological effects in animal species.Sequencing and de novo draft assemblies of a fathead minnow (Pimephales promelas) reference genome.Quantitative proteomics in teleost fish: insights and challenges for neuroendocrine and neurotoxicology research.The Role of Omics in the Application of Adverse Outcome Pathways for Chemical Risk Assessment.Age matters: Developmental stage of Danio rerio larvae influences photomotor response thresholds to diazinion or diphenhydraminePharmaceutical Metabolism in Fish: Using a 3-D Hepatic In Vitro Model to Assess Clearance.Pharmaceuticals in the aquatic environment: a critical review of the evidence for health effects in fish.Zebrafish Embryo as an In Vivo Model for Behavioral and Pharmacological Characterization of Methylxanthine Drugs.Zebrafish: as an integrative model for twenty-first century toxicity testing.Zebrafish as a systems toxicology model for developmental neurotoxicity testing.In silico analysis of the conservation of human toxicity and endocrine disruption targets in aquatic species.Ecological effects of pharmaceuticals in aquatic systems--impacts through behavioural alterations.Effects of environmental exposure to diazepam on the reproductive behavior of fathead minnow, Pimephales promelas.Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish.Pharmaceuticals and personal care products: A critical review of the impacts on fish reproduction.Widespread occurrence and potential for biodegradation of bioactive contaminants in Congaree National Park, USA.Determining potential adverse effects in marine fish exposed to pharmaceuticals and personal care products with the fish plasma model and whole-body tissue concentrations.Uncertainty and variability in human exposure limits - a chemical-specific approach for ciprofloxacin and methotrexate.Comparison of Measured and Predicted Bioconcentration Estimates of Pharmaceuticals in Fish Plasma and Prediction of Chronic Risk.
P2860
Q24608788-234957A4-2FFC-4425-86FB-1A9818815B53Q26825743-A047C777-035F-4739-9CDE-3C6E369C59C7Q26859139-B9EEFCA3-0515-4FCE-8F2A-95F9766329F6Q27308084-C14A5C37-8D53-4732-9A54-BAB5A15CA41BQ28078152-91F6502E-62B0-4090-AA69-ED96048D6F73Q28384182-798E5796-281F-4887-900A-88525CED5248Q28542416-19FF3736-6208-48BF-8018-8C2D311B30B3Q28543995-0A9324CE-0B25-4DCF-A3C1-4B17F2394654Q28817461-6B470E50-CCA7-486F-BF5A-3E51626B144AQ29541727-67228672-B5FD-4437-BC15-C78B6EE347D7Q30390250-199AC374-320F-4138-8D93-B4003E3681BFQ30870407-29BE592E-DB70-49DB-8C4A-08E2EF1F30F3Q33489048-551D5F76-EC05-411F-AA08-46FD6BC52889Q33940284-7118FE97-25AA-4784-904E-2EE6225C0E4AQ34423521-EA80B3B1-4444-4C1C-B29E-64055B411B79Q34423526-CBD8355F-5E01-42C0-AA48-828CE1584C1CQ34423551-69C5137A-2703-456A-AA20-16A54A332664Q34871672-BBD07EE0-62A4-43C7-A6C8-6A7A6C06EB3BQ35044945-120F012B-B621-46E3-82E3-0818A26EF250Q35055209-A3922FE6-237F-46F4-B17A-1F4A03BA2E7AQ35594372-B30613FE-5FB9-4D73-AFBF-FF432D54A8AFQ35674698-3A00EA47-EAC6-48F3-B7D0-17C010AE70EBQ35826081-FB78A8C3-07D0-4524-9B30-811F57DD0B04Q36368664-36C9FC40-82A0-4402-9608-99F68CBA8429Q36376553-EB9B3042-71E5-4A92-AB80-5DC7D648B3C2Q37141525-88A40631-862E-4466-8249-CDB49F3BB191Q37552507-0F1187CC-6E6B-4358-B8F6-FA51DE76B29BQ37708300-EB2298ED-4FF6-4818-AB8D-BA3ABFB36C72Q37729231-C856BD80-309A-411C-B1D2-1688170FE850Q37935725-E8875026-95AE-47B1-80FE-5D90B9E1CC7BQ38238589-1E6C15D9-9785-4EE0-A8FB-588CC7ABAA54Q38259547-C312D421-F18A-41F7-980A-0DC37FC2753FQ38269160-8893C5E1-6D4C-4D65-A68A-584B87D97D67Q38415538-0F2AF200-FE0A-4319-BF9F-8A917A9793F2Q38444377-86779BEB-E5D2-4CA9-AA21-49155FB7C76EQ38461963-F6718A2C-98F7-4A23-B961-29D5F27A0413Q38557360-EC0A870D-6F27-4AFD-A37B-AF90D27C1C80Q38648952-0FF92531-A2AE-4C85-A796-264685B5BADBQ38663357-72FA3332-BF2A-4B16-981F-DCF8E7C704BCQ38785088-5A7283E2-A20A-432F-8AA1-0F41F287A859
P2860
Evolutionary conservation of human drug targets in organisms used for environmental risk assessments.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Evolutionary conservation of h ...... nvironmental risk assessments.
@en
Evolutionary conservation of h ...... nvironmental risk assessments.
@nl
type
label
Evolutionary conservation of h ...... nvironmental risk assessments.
@en
Evolutionary conservation of h ...... nvironmental risk assessments.
@nl
prefLabel
Evolutionary conservation of h ...... nvironmental risk assessments.
@en
Evolutionary conservation of h ...... nvironmental risk assessments.
@nl
P2093
P356
P1476
Evolutionary conservation of h ...... environmental risk assessments
@en
P2093
Alexandra Jauhiainen
Erik Kristiansson
Olle Nerman
P304
P356
10.1021/ES8005173
P407
P577
2008-08-01T00:00:00Z